Skip to main content
Tempest Therapeutics, Inc. logo

Tempest Therapeutics, Inc. — Investor Relations & Filings

Ticker · TPST ISIN · US69014Q1013 US Professional, scientific and technical activities
Open in API
Filings indexed 986 across all filing types
Latest filing 2014-07-02 Director's Dealing
Country US United States of America
Listing US TPST

About Tempest Therapeutics, Inc.

https://www.tempesttx.com/

Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates and cell therapies. The company develops first-in-class therapeutics that combine tumor-targeted and immune-mediated mechanisms to treat cancer. Its lead product candidate is amezalpat (TPST-1120), an oral, selective PPARα antagonist being evaluated in a global, randomized combination study for hepatocellular carcinoma. In addition to its small molecule platform, the company is also developing dual-chimeric antigen receptor (CAR) T-cell programs.

Recent filings

Filing Released Lang Actions
4
Director's Dealing
2014-07-02 English
4
Director's Dealing
2014-07-02 English
4
Director's Dealing
2014-06-25 English
4
Director's Dealing
2014-06-25 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated June 13, 2014. It includes disclosures about the departure and appointment of directors and officers, specifically a stock option grant to the CEO, and detailed voting results from the 2014 annual meeting of stockholders. The voting results include election of directors, approval of a stock incentive plan, and ratification of the independent auditor. The presence of Item 5.02 (changes in directors or officers) and Item 5.07 (submission of matters to a vote of security holders) indicates this is a report on management changes and voting results. The document is not a full annual report, audit report, or earnings release, but rather a regulatory filing reporting management changes and voting outcomes. Therefore, the classification is Declaration of Voting Results & Voting Rights Announcements (DVA) because it contains official voting results from the annual meeting, and also includes management changes disclosures. However, since the voting results are detailed and central, DVA is the best fit.
2014-06-19 English
4
Director's Dealing
2014-06-19 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.